Press Releases
-
Recombinant protein-based ‘GBP510’ with GSK pandemic adjuvant demonstrates superior neutralising tit...2022.04.29 -
For 4,037 adults over 18 years of age, GBP510(AS03) proves non-inferiority to an authorized COVID-19...2022.04.25 -
SK began developing an innovative technology to prevent viral infections and relieve symptoms throug...2022.04.13 -
SK submitted a post-approval change application for Nuvaxovid™, Novavax’ recombinant protein-based C...2022. 04. 07 -
Efficacy similar to adults 18 years and older with robust cross-reactive immune responses against Om...2022.03.23 -
* A homologous booster trial of GBP510 will be initiated * A heterologous booster trial is being con...2022. 03. 22 -
- A vaccine platform with long-term well-understood safety and efficacy is expected to induce more p...2022. 02. 09 -
Recruitment of global Phase III clinical trial of ‘GBP510’ completed, with vaccine expected to be au...2022. 01. 18 -
The first approval of a recombinant protein nanoparticle COVID-19 vaccine with proven efficacy and s...2022. 01. 12 -
SK bioscience-Novavax Extend Collaboration and Contract Manufacturing Agreements of COVID-19 VaccineSK-Novavax amended the Collaboration and License agreement for contract manufacturing of ‘NVX-CoV237...2021. 12. 24 -
SK will develop a vaccine candidate against sarvecovirus- the group of viruses containing SARS-CoV ...2021. 12. 21 -
SK bioscience (CEO Jae-Yong Ahn) announced the promotion of new executives for 2022 on December 2nd...2021. 12. 2